Insmed (NASDAQ:INSM) Announces Earnings Results

Insmed (NASDAQ:INSM) released its earnings results on Thursday. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15), Zacks reports. The business had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed updated its FY 2025 guidance to EPS.

Insmed Trading Down 0.6 %

Shares of Insmed stock traded down $0.53 during trading on Friday, hitting $83.09. The company’s stock had a trading volume of 615,388 shares, compared to its average volume of 1,885,705. The stock has a market cap of $14.86 billion, a price-to-earnings ratio of -14.97 and a beta of 1.11. Insmed has a 52 week low of $21.92 and a 52 week high of $84.91. The stock has a 50-day moving average price of $74.11 and a two-hundred day moving average price of $73.52. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insiders Place Their Bets

In related news, CEO William Lewis sold 2,978 shares of Insmed stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the transaction, the chief executive officer now directly owns 392,589 shares of the company’s stock, valued at $24,874,439.04. The trade was a 0.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Martina M.D. Flammer sold 6,172 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the sale, the insider now directly owns 101,549 shares of the company’s stock, valued at $6,462,578.36. This represents a 5.73 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 532,207 shares of company stock valued at $41,400,465. 4.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research note on Wednesday. Guggenheim lifted their price target on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Morgan Stanley upped their price objective on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and an average price target of $90.79.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.